Geron Corp - GERN STOCK NEWS

Geron Corporation (Nasdaq: GERN), a biopharmaceutical company, announced that CEO John A. Scarlett will present at the H.C. Wainwright BioConnect Conference. The pre-recorded presentation will be accessible starting at 7 a.m. ET on January 10, 2022, via a provided link and will be archived for 30 days post-event. Geron focuses on a first-in-class telomerase inhibitor, imetelstat, currently in two Phase 3 clinical trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

Geron Corporation (Nasdaq: GERN) announced the grant of a non-statutory stock option for 50,000 shares of common stock to a newly hired employee, effective December 15, 2021. The option has an exercise price of $1.37 per share, matching the stock's closing price on that date. It carries a 10-year term and vests over four years, with 12.5% vesting after six months and the remainder in equal installments over the next 42 months, subject to continued employment. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan.

Geron Corporation (GERN) announced three poster presentations at the 63rd American Society of Hematology Annual Meeting regarding imetelstat, its novel telomerase inhibitor. The posters showcase ongoing Phase 3 trials for imetelstat in lower risk myelodysplastic syndromes (MDS) and refractory myelofibrosis (MF), emphasizing its potential clinical benefits and safety. Results from the IMerge Phase 3 trial are expected in early January 2023, while the IMpactMF trial continues patient enrollment. Imetelstat has received Fast Track designation from the FDA for specific hematological conditions.

Geron Corporation (NASDAQ: GERN) announces the appointment of Edward Koval as Executive Vice President and Chief Business Officer, enhancing its executive team. Koval brings over 25 years of biotech experience and will focus on business development related to Geron's imetelstat and telomerase inhibitor franchises. Top-line results from the IMerge Phase 3 trial are expected in 13 months, while an interim analysis of the IMpactMF trial is anticipated in 2024. This leadership shift aims to maximize the potential of Geron's innovative treatments in hematologic malignancies.

Geron Corporation (Nasdaq: GERN) announced the granting of a non-statutory stock option for 80,000 shares as an inducement for a new employee starting on November 17, 2021. The exercise price is $1.42 per share, matching the stock's closing price on the grant date. The option has a 10-year term, with a vesting schedule over four years, starting with 12.5% after six months, then monthly installments. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan.

Geron Corporation (Nasdaq: GERN), a biopharmaceutical firm specializing in hematologic malignancies, announced that Dr. John A. Scarlett will present a company overview at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 p.m. ET. The presentation will be available via a live webcast on Geron's Investor Relations website and archived for 30 days thereafter. Geron is currently conducting two Phase 3 trials for its telomerase inhibitor, imetelstat, targeting lower risk myelodysplastic syndromes and refractory myelofibrosis.

Geron Corporation (Nasdaq: GERN) reported strong evidence of imetelstat's disease-modifying activity, targeting lower risk myelodysplastic syndromes (MDS) and refractory myelofibrosis (MF). Key insights were presented at an Investor Event, highlighting significant unmet needs in these conditions. Geron plans three new clinical programs for imetelstat, including combinations with existing therapies, and anticipates peak revenue exceeding $3 billion in these indications. Financially, Geron reported a net loss of $26.7 million for Q3 2021, with cash reserves of $215.8 million expected to fund operations through early 2023.

Geron Corporation (NASDAQ: GERN) has announced that imetelstat, their first-in-class telomerase inhibitor, has received the Innovation Passport designation from the UK's MHRA under the Innovative Licensing and Access Pathway. This designation aims to expedite the regulatory review process, allowing a 150-day accelerated assessment for Marketing Authorization Applications. The IMerge Phase 2 study demonstrated durable transfusion independence in lower risk MDS patients. Geron is conducting two ongoing Phase 3 clinical trials for imetelstat.